Continuous glucose monitors, the small wearable sensors that track blood sugar around the clock, can substantially help adults with type 2 diabetes who do not use insulin, according to the largest clinical trial of its kind, published in the New England Journal of Medicine. Participants using the monitors spent approximately five more hours each day with their blood sugar in the target range, a meaningful improvement in a condition where daily control strongly influences long-term health.
What the Trial Found
The study focused on a group that has often been overlooked in diabetes technology research: people with type 2 diabetes who manage their condition with oral medication, diet and activity rather than insulin injections. Continuous glucose monitors have long been standard for many people with type 1 diabetes and for insulin users, but evidence for everyone else has been thinner, and insurance coverage has often followed that gap.
According to the research summary from the University of Colorado Anschutz Medical Campus, whose researchers were involved in the work, monitor users spent roughly five additional hours a day in their healthy blood sugar range compared with those relying on traditional monitoring. Five hours is not a marginal gain; it represents a large share of a person’s waking day spent in safer territory.
Why Time in Range Matters
Doctors increasingly judge diabetes control not only by HbA1c, a single average measured every few months, but by time in range — the proportion of the day blood sugar stays between agreed lower and upper limits. Every extra hour in range means less exposure to the highs that damage blood vessels, nerves, eyes and kidneys over time, and fewer of the lows that can cause dizziness and confusion.
A continuous monitor changes behaviour because it makes the invisible visible. Instead of a few finger-prick readings a day, users see a live graph. They can watch their glucose climb after a particular meal, fall during a walk, or creep upward overnight. That feedback loop turns abstract dietary advice into personal, immediate information, and many users naturally adjust portion sizes, meal timing and activity in response.
A Tool, Not a Treatment on Its Own
Researchers are careful to note that a sensor does not lower blood sugar by itself. The device supplies information; the improvement comes from what patients and clinicians do with it. In the trial setting, that meant education, regular review of the data and support in interpreting patterns. People newly diagnosed, or those building healthier routines while studying or working, may find this kind of feedback especially motivating, in the same way that understanding the skills employers want most in 2026 turns a vague ambition into a concrete plan: clear data makes the next step obvious.
There are practical hurdles too. Sensors must be worn continuously and replaced every one to two weeks, they can occasionally produce inaccurate readings, and some users find alarms or constant data stressful. Cost and coverage remain the largest barriers, which is precisely why strong trial evidence matters: insurers and health systems usually demand exactly this standard of proof before paying for a technology at scale.
What It Could Mean for Coverage and Care
Publication in the New England Journal of Medicine, one of the most influential medical journals in the world, gives the findings unusual weight in policy debates. If coverage expands to more adults with type 2 diabetes who are not on insulin, millions of additional patients could gain access to a tool previously reserved for a narrower group.
Clinicians say the results also strengthen the case for earlier intervention. Type 2 diabetes is progressive, and habits formed while blood sugar is still moderately elevated can delay or prevent complications for years. A monitor worn even for a few months can teach a patient more about their own responses to food, sleep and exercise than years of general advice, and that knowledge persists after the sensor comes off.
The Bottom Line for Patients
Anyone with type 2 diabetes who is curious about continuous monitoring should raise it with their care team, particularly if finger-prick testing feels burdensome or their HbA1c is above target despite medication. The technology is not essential for everyone, and it works best alongside, not instead of, medication, balanced meals, regular movement and sleep.
Still, the direction of the evidence is clear. Diabetes care is moving from occasional snapshots to continuous understanding, and this trial suggests the benefits extend well beyond insulin users. For patients, five more hours a day in the healthy range is not just a statistic on a chart; compounded over months and years, it is time that may protect their vision, their kidneys and their heart — and that makes a small sensor a potentially life-changing piece of technology.